The reality of drug pricing
By Andrew Willis | 01/03/19
High drug prices have been making headlines recently, with a recent U.S. Senate hearing into the matter earlier this week.
Should investors inject their portfolios with some pharma exposure to get behind this trend? Or are there dangerous side-effects to watch out for when getting behind companies selling thousand-dollar doses?